对叶百部碱在制备治疗结肠炎药物中的应用

By regulating the intestinal flora with Stemona alkaloids, a drug for treating ulcerative colitis was prepared, solving the problems of drug resistance and adverse reactions of existing drugs, achieving safe and efficient treatment of colitis, and reducing the burden on patients and research and development costs.

CN122398812APending Publication Date: 2026-07-17JILIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
JILIN UNIVERSITY
Filing Date
2026-06-16
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing drugs for treating ulcerative colitis have drug resistance and adverse reactions, and there is a lack of effective treatment options that regulate the gut microbiota.

Method used

Using stemona alkaloids as the active ingredient, a drug for treating colitis was prepared, which alleviates ulcerative colitis by regulating the intestinal flora.

Benefits of technology

Stemona alkaloids significantly improved the symptoms of DSS-induced colitis, reduced the treatment burden on patients, and had obvious safety and cost advantages, making it suitable for industrial promotion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122398812A_ABST
    Figure CN122398812A_ABST
Patent Text Reader

Abstract

本发明适用于生物医药技术领域，提供了对叶百部碱在制备治疗结肠炎药物中的应用。本发明证实了对叶百部碱通过调节肠道菌群缓解、治疗结肠炎，突破了现有天然产物研究靶点不清晰、机制不明确的局限，同时对叶百部碱来源广泛，提取工艺成熟，相较于传统合成药物，对叶百部碱作为天然化合物，其成分毒性更低，同时相较于新兴益生菌疗法、生物制剂，本发明对应的后续药物开发成本更低，更易实现产业化推广，能降低患者的治疗负担。
Need to check novelty before this filing date? Find Prior Art